Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort
NCT ID: NCT06274333
Last Updated: 2026-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
60 participants
INTERVENTIONAL
2024-02-28
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Tramadol and Dexmedetomidine in the Prevention of Urinary Catheter Discomfort in Urinary Surgery
NCT04314050
Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
NCT06399185
Dexmedetomidine and Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain
NCT06331182
Intrathecal Versus Intravenous Dexmedetomidine in Prostate Transurethral Resection
NCT05525819
Adjuvant Dexmedetomidine and Tramadol in Subcostal Transversus Abdominis Plan Block
NCT05905757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DP group
Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg
Dexmedetomidine 0.5 mic/kg
Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
Paracetamol 10mg/kg
Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
TP group
Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
Tramadol 1mg/kg
Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
Paracetamol 10mg/kg
Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine 0.5 mic/kg
Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
Tramadol 1mg/kg
Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
Paracetamol 10mg/kg
Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA (The American Society of Anesthesiologists) I or II,
* undergo percutaneous nephrolithotomy (PCNL)
Exclusion Criteria
* Opioid users
* Bladder obstruction,
* Benign prostatic hyperplasia
* Overactive bladder (OAB) defined as frequency \_3 times at night or \_8 times within 24 hours.
20 Years
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Al-Azhar University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Neveen Abd El Maksoad Kohaf
Lecturer of Clinical Pharmacy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neveen Kohaf
Cairo, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC.18.1.2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.